We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Run liquid biopsy RGCC on fresh tumor or blood & treat accordingly to sensitivity.
Rego can be be an option but dosage must be lowest as RPLS is possible same as with avastin.
Summary GENE MARKERS ARE NEEDED to further elucidate correct chemotype for this patient
treat post operative necrosis
1) Why was the adjuvant TMZ only 3 mos? 2) Why did an unmethylated GBM NOT get Novo TTF-1 in adjuvant or concurrent setting 3) Candidate for AGILE study?
1. FTB map. If it shows likely tumor, stereotactic radiosurgery to the new lesion, or LITT.
3. Val-083. Possibly via the AGILE study but might be better to get it on compassionate use along with Optune.
4. Viral therapy. Maybe PVSRIPO + Pembrolizumab.
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.